Evaluation of the EGFR-Inhibitor Zalutumumab Given With Primary Curative (Chemo)radiation Therapy to Patients With Squamous Cell Carcinoma of the Head and Neck: Results of the DAHANCA 19 Randomized Phase 3 Trial : Definitive Management of Head-and-Neck Squamous Cell Carcinoma

J Eriksen,Christian Maare,Jorgen Johansen,Hanne Primdahl, J F Evensen, C A Kristensen, L J Andersen,Jens Overgaard

mag(2014)

引用 23|浏览3
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要